ブース番号3H-32
カテゴリー原料
Formosa Pharmaceuticals, Inc.
小間番号：3H-32
カテゴリー：原料
企業情報
Email：
waynewei@formosapharma.com
TEL： +886-2-2755-7659
住所： 8F-6, No.57, Fuxing N. Rd., Songshan Dist., Taipei City 105 105404
URL：
https://www.formosapharma.com/
Formosa Pharmaceuticals is a clinical stage biotech with a primary focus in ophthalmology and oncology.
Our Assets and Technology:
-APNT® formulation platform, from which APP13007 is developed, is available for regional licensing, CDMO services, or co-development.
-TSY-110 program: a biosimilar of Kadcyla®, which is available for licensing or co-development.
-APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%), a novel formulation for the treatment of inflammation and pain following ocular surgery, is approved by the US FDA in 2024.
Our Assets and Technology:
-APNT® formulation platform, from which APP13007 is developed, is available for regional licensing, CDMO services, or co-development.
-TSY-110 program: a biosimilar of Kadcyla®, which is available for licensing or co-development.
-APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%), a novel formulation for the treatment of inflammation and pain following ocular surgery, is approved by the US FDA in 2024.
企業情報
| 住所 | 8F-6, No.57, Fuxing N. Rd., Songshan Dist., Taipei City 105 105404 |
|---|---|
| TEL | +886-2-2755-7659 |
| URL | https://www.formosapharma.com/ |
| waynewei@formosapharma.com |
| 出展製品・サービス |
APNT Nanoaparticle Formulation Technology Platform TSY-110 – Kadcyla (T-DM1) Biosimilar APP13007 (BYQLOVI) Clobetasol Propionate Ophthalmic Suspension |
|---|
出展製品・サービス
APNT Nanoaparticle Formulation Technology PlatformTSY-110 – Kadcyla (T-DM1) BiosimilarAPP13007 (BYQLOVI) Clobetasol Propionate Ophthalmic Suspension